Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Human CCL (chronic lymphocytic leukemia) cells|
|Storage buffer||PBS, pH 7.4|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1 ug/ml|
|Immunocytochemistry (ICC)||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern.
MA1-10126 was used in flow cytometry to assess the immunological status after Bz-treatment during early indeterminate Chagas disease
|Sathler-Avelar R,Vitelli-Avelar DM,Massara RL,de Lana M,Pinto Dias JC,Teixeira-Carvalho A,Elói-Santos SM,Martins-Filho OA||Microbes and infection (10:103)||2008|
|Not Applicable||Not Cited||
Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?
MA1-10126 was used in flow cytometry to characterize the kinetics of the adaptive immune response following primary 17DD vaccination in order to clarify how it elicits such broad protection
|Martins MA,Silva ML,Marciano AP,Peruhype-Magalhães V,Eloi-Santos SM,Ribeiro jG,Correa-Oliveira R,Homma A,Kroon EG,Teixeira-Carvalho A,Martins-Filho OA||Clinical and experimental immunology (148:90)||2007|
FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver.
MA1-10126 was used in flow cytometry to assess the effects of the FLK-2/FLT-3 ligand on the growth of human fetal liver progenitors.
|Muench MO,Roncarolo MG,Menon S,Xu Y,Kastelein R,Zurawski S,Hannum CH,Culpepper J,Lee F,Namikawa R||Blood (85:963)||1995|
AW495831; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CD19; Differentiation antigen CD19; T-cell surface antigen Leu-12
B4; CD19; CVID3